ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01345357
Recruitment Status : Completed
First Posted : May 2, 2011
Last Update Posted : January 18, 2013
Sponsor:
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Cephalon )

April 19, 2011
May 2, 2011
January 18, 2013
May 2011
December 2012   (Final data collection date for primary outcome measure)
Determination of the maximum tolerated dose (MTD) of CEP-9722 in combination with gemcitabine and cisplatin in patients with advanced solid tumors or mantle cell lymphoma. [ Time Frame: Baseline and endpoint (as soon as possible after Day 21 of the last cycle) ]
To determine the maximum tolerated dose of CEP-9722, as defined by dose-limiting toxicities (DLTs) reported during the second 21-day treatment cycle (the first cycle of CEP-9722 administration).
Determination of the maximum tolerated dose (MTD) of CEP-9722 in combination with gemcitabine and cisplatin in patients with advanced solid tumors [ Time Frame: Baseline and endpoint (End of the second 21 day cycle or up to 42 days following first dose) ]
To determine the maximum tolerated dose of CEP-9722, as defined by dose-limiting toxicities (DLTs) reported during the second 21-day treatment cycle (the first cycle of CEP-9722 administration).
Complete list of historical versions of study NCT01345357 on ClinicalTrials.gov Archive Site
  • Evaluate the safety and tolerability of CEP-9722 in combination with gemcitabine and cisplatin [ Time Frame: During the entire study, a minimum of 6 wks (two 21-day cycles) up to a maximum of 18 wks (six 21-day cycles). ]
    Assessed by the occurrence of adverse events, clinical laboratory test results, vital signs measurements, electrocardiogram (ECG) findings, physical examination findings, and concomitant medication usage. Creatinine clearance will be calculated according to the Cockroft-Gault formula. An audiogram will be performed at screening and repeated during the study if clinically relevant according to the investigator. Pts who complete or withdraw from treatment will have final procedures/assessments performed as soon as possible, after day 21 of the last cycle, at the end-of-treatment visit.
  • Cmax pharmacokinetics parameter [ Time Frame: Days 2 and 7 of Cycle 2 and Day 7 of Cycle 3 ]
    To characterize the pharmacokinetics profile of CEP-8983 (the active moiety of CEP-9722) following administration of CEP-9722, through measurement of the Maximum observed drug Concentration (Cmax).
  • AUC pharmacokinetics parameter [ Time Frame: Days 2 and 7 of Cycle 2 and Day 7 of Cycle 3 ]
    To characterize the pharmacokinetics profile of CEP-8983 (the active moiety of CEP-9722) following administration of CEP-9722, through measurement of the Area Under the plasma concentration-time Curve (AUC).
  • Pharmacodynamics assessment [ Time Frame: Screening and Day 2 of Cycle 2 at predose, and at 2 and 6 hours after administration of CEP-9722 ]
    To determine the extent of poly-adenosine diphosphate ribose polymerase (PARP) inhibition in peripheral blood mononuclear cells following administration of CEP-9722
  • Efficacy - will be assessed by Tumor response evaluation of each patient [ Time Frame: Screening, cycles 3 and 6, and every 2 cycles after cycle 6 until disease progression ]
    Tumor response will be determined using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 guidelines, when possible for patients with solid tumors. For patients with mantle tumors, tumor response may be evaluated by the International Working Group criteria.
  • Evaluate the safety and tolerability of CEP-9722 in combination with gemcitabine and cisplatin [ Time Frame: Throughout the entire Study Period, a minimum of 6 weeks (two 21-day cycles) up to a maximum of 18 weeks (six 21-day cycles) ]
    Assessed by the occurrence of adverse events, clinical laboratory test results, vital signs measurements, electrocardiogram (ECG) findings, physical examination findings, and concomitant medication usage.
  • Cmax pharmacokinetics parameter [ Time Frame: Days 2 and 7 of Cycle 2 and Day 7 of Cycle 3 ]
    To characterize the pharmacokinetics profile of CEP-8983 (the active moiety of CEP-0722) following administration of CEP-9722, through measurement of the Maximum observed drug Concentration (Cmax).
  • AUC pharmacokinetics parameter [ Time Frame: Days 2 and 7 of Cycle 2 and Day 7 of Cycle 3 ]
    To characterize the pharmacokinetics profile of CEP-8983 (the active moiety of CEP-0722) following administration of CEP-9722, through measurement of the Area Under the plasma concentration-time Curve (AUC).
  • Pharmacodynamics assessment [ Time Frame: Screening and Day 2 of Cycle 2 at predose, and at 2 and 6 hours after administration of CEP-9722 ]
    To determine the extent of poly-adenosine diphosphate ribose polymerase (PARP) inhibition in peripheral blood mononuclear cells following administration of CEP-9722
  • Efficacy - will be assessed by Tumor response evaluation of each patient [ Time Frame: Baseline, Days 15-21 of Cycles 3 and 6, Endpoint (end of treatment visit) ]
    Tumor response will be determined using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 guidelines
Not Provided
Not Provided
 
Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma
A Dose-Escalation Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-9722 (a PARP 1 and PARP 2 Inhibitor) in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma
The primary objective of the study is to determine the maximum tolerated dose (MTD) of CEP-9722 in combination with gemcitabine and cisplatin in patients with advanced solid tumors or mantle cell lymphoma.
Not Provided
Interventional
Phase 1
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Solid Tumors or Mantle Cell Lymphoma
  • Drug: CEP-9722
    CEP-9722 will be administered orally from day 2 through day 7 of each cycle beginning with cycle 2. The starting dose will be 150 mg twice daily. Following cycle 2, the dose will either be decreased to 150 mg daily or increased to 200 mg twice daily in a cohort of 3 to 4 new patients. Subsequent cycles will increase the dose by 100 mg twice daily in cohorts of 3 to 4 patients (with criteria to expand to 6 patients) to a maximum of 400 mg twice daily. Patients must receive CEP-9722 to remain in the study. Once treatment with CEP-9722 is discontinued, patients will withdraw from the study.
  • Drug: Gemcitabine
    Gemcitabine will be administered at 1250 mg/m^2 intravenously on day 1 and day 8 of each 21-day cycle. Dosage reduction may be applied on day 8 (within a cycle) or on day 1 of the next cycle based upon the grade of toxicity experienced by the patient.
  • Drug: Cisplatin
    Cisplatin will be administered at 75 mg/m^2 intravenously on day 1 of each cycle, after the infusion of gemcitabine. Dosage reduction may be applied on day 1 of the next cycle based upon the grade of toxicity experienced by the patient.
Experimental: CEP-9722 in combination with Gemcitabine and Cisplatin
Study drugs will be administered in cycles of 21 days for up to 6 cycles. CEP-9722 treatment will be initiated at cycle 2. After cycle 3, patients may discontinue gemcitabine and/or cisplatin for reasons of tolerability, at the discretion of the investigator.
Interventions:
  • Drug: CEP-9722
  • Drug: Gemcitabine
  • Drug: Cisplatin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
24
32
January 2013
December 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Written informed consent is obtained. The patient has a either a histologically or cytologically confirmed malignant advanced solid tumor or a mantle cell lymphoma (and has experienced failure of as least 1 previous therapy) and the patient may benefit from the combination of gemcitabine and cisplatin.
  • The patient has measurable or nonmeasurable disease evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guidelines.
  • The patient is a man or woman at least 18 years of age.
  • The patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • The patient has a life expectancy of 12 weeks or more.
  • The patient has adequate hematologic assessments and adequate renal and hepatic function as specified in the study protocol
  • The patient has audiogram results without clinically significant abnormalities.
  • The patient may have had chemotherapy provided that at least 3 weeks have elapsed and prior sequelae have resolved. If the patient has had prior radiation (curative or palliative) or prior treatment with nitrosoureas, a minimum of 4 weeks and 6 weeks, respectively, must have elapsed before treatment with CEP-9722.
  • The patient has had no immunotherapy, including monoclonal antibody therapy, for at least 4 weeks and no hormonal therapy for at least 1 week, with the exception of patients with prostate cancer, who may continue hormonal therapy.
  • Written informed consent is obtained.
  • Agreement by women of childbearing potential (not surgically sterile or 2 years postmenopausal) to use a medically accepted method of contraception and continue the use of this method for the duration of the study and for 90 days after participation in the study. Acceptable methods of contraception include abstinence, barrier method with spermicide, intrauterine device (IUD), or steroidal contraceptive (oral, transdermal, implanted, and injected) in conjunction with a barrier method.
  • Agreement by men not surgically sterile or who are capable of producing offspring to practice abstinence or use a barrier method of birth control, and continue use of this method for the duration of the study and for 6 months after participation in the study.

Exclusion Criteria:

  • With the exception of cancer, the patient has any serious or uncontrolled surgical, medical, or psychiatric history that could prevent compliance with study procedures, or compromise the integrity of the study.
  • The patient has any of the protocol specified risk factors for Torsade de Pointes
  • The patient has a brain lesion requiring systemic therapy with corticosteroids or anti-convulsive agents.
  • The patient has previous hypersensitivity reactions to 1 or more of the components of the CEP-9722, gemcitabine, or cisplatin drug products.
  • The patient is a pregnant or breast-feeding woman. (Any women becoming pregnant during the study will be withdrawn from the study.)
  • The patient is participating in another interventional clinical study at the time of enrollment or has participated in another interventional clinical study within 4 weeks prior to enrollment.
  • The patient has any malabsorption syndrome and/or prior gastrectomy
  • The patient has a concomitant uncontrolled and/or chronic infection or severe systemic disease.
  • The patient has had previous treatment with another poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor.
  • The patient is unable to swallow tablets.
  • The patient cannot interrupt continuous treatment with proton pump inhibitors and/or H2 receptor antagonists.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Belgium,   France
 
 
NCT01345357
C9722/1092
2010-023658-36 ( EudraCT Number )
Yes
Not Provided
Not Provided
Teva Pharmaceutical Industries ( Cephalon )
Cephalon
Not Provided
Study Director: Sponsor's Medical Expert, MD Cephalon, France
Teva Pharmaceutical Industries
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP